1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019

Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019

  • March 2015
  • -
  • Infiniti Research Limited
  • -
  • 103 pages

About
According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration.

TechNavio's analysts forecast the Global CKD Drugs market to grow at a CAGR of 1.21 percent over the period 2014-2019.


Covered in this Report
The Global CKD Drugs Market can be divided into two segments: Route of Administration which includes oral, SC, and IV and Mechanism of Action which includes ARBs, ACEIs, ESAs, PH Binders, and Vasodilators. This report covers the present scenario and the growth prospects of the Global CKD Drugs market for the period 2014–2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CKD that are available in the market.

TechNavio's report, the Global CKD Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA and APAC regions; it also covers the Global CKD Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.


Key Regions
• Americas
• EMEA
• APAC


Key Vendors
• Actavis PLC
• Amgen Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd
• Sanofi

Other Prominent Vendors
• Abbott Laboratories
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Cara Therapeutics
• FibroGen
• Keryx Biopharmaceuticals
• Reata Pharmaceuticals
• OPKO Health
• Pharmacosmos
• Raptor Pharmaceuticals
• Regulus Therapeutics
• Rockwell Medical
• Shield Therapeutics
• Takeda Pharmaceuticals
• Vifor Pharma Ltd
• Xenetic Biosciences
• ZS Pharma


Market Driver
• Increase in Associated Disorders with CKD
• For a full, detailed list, view our report


Market Challenge
• Genericization of Major Brands
• For a full, detailed list, view our report


Market Trend
• Approval of New Pipeline Drugs
• For a full, detailed list, view our report


Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Table Of Contents

Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Aranesp
04.1.2 Epogen/Procrit
04.1.3 Mircera
04.1.4 Renvela
04.1.5 Avapro
04.1.6 Bystolic
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disease Overview
07.1 Etiology
07.2 Epidemiology
07.2.1 Mortality
07.2.2 Prevalence of CKD
08. Pipeline Analysis
08.1 Emerging Treatment Options
09. Market Landscape
09.1 Market Overview
09.2 Market Size and Forecast
09.3 Five Forces Analysis
10. Segmentation of Global CKD Market by Route of Administration
10.1 Oral
10.2 SC
10.3 IV
11. Segmentation of Global CKD Market by Mechanism of Action
11.1 ARBs
11.2 ACEIs
11.3 ESAs
11.4 PH Binders
11.5 Vasodilators
12. Geographical Segmentation
12.1 CKD Drugs Market in Americas
12.1.1 Market Size and Forecast
12.2 CKD Drugs Market in EMEA Region
12.2.1 Market Size and Forecast
12.3 CKD Drugs Market in APAC Region
12.3.1 Market Size and Forecast
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 Competitive Assessment of Top Drugs Used for CKD Treatment
20.2.2 Amgen
20.2.3 Actavis
20.2.4 Johnson and Johnson
20.2.5 F. Hoffmann-La Roche
20.2.6 Sanofi
20.3 Other Prominent Vendors
21. Key Vendor Analysis
21.1 Amgen
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Product Portfolio by Revenue 2013
21.1.5 Business Segmentation by Revenue 2012 and 2013
21.1.6 Geographical Segmentation by Revenue 2013
21.1.7 Business Strategy
21.1.8 Recent Developments
21.1.9 SWOT Analysis
21.2 Actavis
21.2.1 Key Facts
21.2.2 Business Description
21.2.3 Business Segmentation
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Sales by Geography
21.2.6 Business Strategy
21.2.7 Key Information
21.2.8 SWOT Analysis
21.3 Johnson and Johnson
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation by Revenue 2013
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Geographical Segmentation by Revenue 2013
21.3.6 Business Strategy
21.3.7 Recent Developments
21.3.8 SWOT Analysis
21.4 F. Hoffmann-La Roche Ltd.
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Sales by Geography
21.4.6 Business Strategy
21.4.7 Key Information
21.4.8 SWOT Analysis
21.5 Sanofi SA
21.5.1 Key Facts
21.5.2 Business Description
21.5.3 Business Segmentation
21.5.4 Revenue by Business Segmentation
21.5.5 Revenue Comparison 2012 and 2013
21.5.6 Sales by Geography
21.5.7 Business Strategy
21.5.8 Key Developments
21.5.9. SWOT Analysis
22. Other Reports in this Series

List of Exhibits
Exhibit 1: Segmentation of Global CKD Drugs Market
Exhibit 2: Market Research Methodology
Exhibit 3: Stages of CKD
Exhibit 4: Causes of CKD
Exhibit 5: Prevalence of CKD among NHANES (US) Participants by CKD Stage 1988-2012
Exhibit 6: Global CKD Drugs Market 2014-2019 (US$ billion)
Exhibit 7: Drivers and Challenges in Global CKD Drugs Market
Exhibit 8: Segmentation of Global CKD Drugs Market by Route of Administration
Exhibit 9: Segmentation of Global CKD Drugs Market by Mechanism of Action
Exhibit 10: Segmentation of Global CKD Drugs Market by Geography 2014
Exhibit 11: Segmentation of Global CKD Drugs Market by Geography 2019
Exhibit 12: Segmentation of Global CKD Drugs Market by Geography 2014-2019
Exhibit 13: CKD Drugs Market in Americas 2014-2019 (US$ billion)
Exhibit 14: CKD Drugs Market in EMEA Region 2014-2019 (US$ billion)
Exhibit 15: CKD Drugs Market in APAC Region 2014-2019 (US$ billion)
Exhibit 16: Comparison of Percentage of Population Age 65 and Older 2012 and 2050
Exhibit 17: Revenue Comparison of Top Drugs Used for Treatment of CKD 2013 (US$ million)
Exhibit 18: Epogen: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
Exhibit 19: Aranesp: Revenue Comparison and YoY Growth 2011-2013 (US$ million)
Exhibit 20: Bystolic: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
Exhibit 21: Procrit: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
Exhibit 22: Mircera: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
Exhibit 23: Renvela: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
Exhibit 24: Avapro: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
Exhibit 25: Amgen: Business Segmentation by Revenue 2013
Exhibit 26: Amgen: Product Portfolio by Revenue 2013
Exhibit 27: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 28: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 29: Global CKD Drugs Market Market Business Segmentation 2013
Exhibit 30: Global CKD Drugs Market Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 31: Actavis : Sales by Geography (in US$ million)
Exhibit 32: Johnson and Johnson: Business Segmentation by Revenue 2013
Exhibit 33: Johnson and Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 34: Johnson and Johnson: Geographical Segmentation by Revenue 2013
Exhibit 35: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 36: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 37: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 38: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 39: Sanofi SA: Business Segmentation
Exhibit 40: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 41: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 42: Sanofi SA: Sales Revenue by Geographical Segmentation 2013

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Systemic lupus erythematosus, also commonly known as lupus, is an autoimmune disease which results in inflammation of tissues in the body with common symptoms like fever, fatigue, skin rashes, malaise, ...

European Market Overview for Diabetes Monitoring, Treatment and Drug Delivery 2016 - MedView

European Market Overview for Diabetes Monitoring, Treatment and Drug Delivery 2016 - MedView

  • $ 4995
  • Industry report
  • September 2016
  • by iData Research, Inc.

The European diabetes diagnosis, treatment and drug delivery market increased in 2015 and growth is expected to persist over the forecast period. Market growth will be driven by the growing prevalence ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.